A Phase 1, Adaptive, Single and Multiple Ascending Dose Study of EMA401 Sodium Salt Administered Orally in Healthy, Adult Males to Determine the Maximum Tolerated Dose and Pharmacokinetic Profiles

Trial Profile

A Phase 1, Adaptive, Single and Multiple Ascending Dose Study of EMA401 Sodium Salt Administered Orally in Healthy, Adult Males to Determine the Maximum Tolerated Dose and Pharmacokinetic Profiles

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs EMA 401 (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions
  • Sponsors Spinifex Pharmaceuticals
  • Most Recent Events

    • 23 Jan 2015 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
    • 11 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top